Akèy › Kansè Poumon ki pa ti selil › Pennsylvania › Lancaster
Etid klinik pou Kansè Poumon ki pa ti selil nan Lancaster, PA
7 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Lancaster (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Ap rekriteFaz 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Ap rekriteFaz 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Ap rekriteFaz 3
- Lancaster General Hospital, Lancaster
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Lancaster General Hospital (UPenn), Lancaster
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Lancaster
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Lancaster
- Maladi kadyovaskilè5 etid
- Ensifizyans kadyak5 etid
- Kansè nan tete4 etid
- Kansè pwostat4 etid
- Kansè Metastatik4 etid
- Kansè poumon3 etid
- Amblyopi3 etid
- Maladi kè3 etid
- Kansè vejik3 etid
- Kansè Vezik ki pa envazif miskilè3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.